May 15 - 17, 2017
Keynote Speaker: Vijay K. Kuchroo (Harvard Institutes of Medicine)
Learn about most recent advances in basic, translational, and clinical research on the rare, acquired disorder, Myasthenia Gravis, as well as implications of this research on a range of related autoimmune and neuromuscular diseases.
Thursday, May 25, 2017 | 9:00 AM - 5:00 PM
Keynote Speaker: Craig Thompson (Memorial Sloan Kettering Cancer Center)
This symposium will highlight insights into tumor metabolism from leaders in the field and explore how this information is being used to design safe and effective, metabolism-targeted therapies.
June 13 - 14, 2017
Keynote Speaker: Michael V. Sofroniew (David Geffen School of Medicine at UCLA)
The conference will explore neuroregenerative processes and identify strategies for translating knowledge into treatments for neurodegenerative diseases and nervous system injuries.
June 21 - 22, 2017
Experience a public-facing dialogue exploring the nuanced ethical and scientific rationale behind randomized controlled clinical trials, accelerated alternatives, and the implications of these discussions on drug approval and patient interests.
Tuesday, September 26, 2017 | 9:00 AM - 5:00 PM
Speakers: Nathan J. Baird (National Heart, Lung and Blood Institute, NIH), Matthew D. Disney (Scripps Research Institute), John A. Howe (Merck Research Laboratories), David H. Mathews (University of Rochester), Kevin M. Weeks (University of North Carolina at Chapel Hill), Steven C. Zimmerman (University of Illinois)
This symposium will cover approaches for targeting RNA with small and large molecules. The relevance of RNA splicing, microRNA, and RNA repeat expansions to human disease, and novel approaches for selectively modulating RNA function will be discussed.
Tuesday, April 25, 2017 | 9:00 AM - 5:00 PM
Keynote Speaker: V. Michael Holers (University of Colorado School of Medicine)
The complement system is the first line of defense against infection, however we have yet to capitalize on its therapeutic potential. This symposium will focus on novel insights into the complement pathway in a number of clinical disorders.
Tuesday, April 11, 2017 | 9:00 AM - 5:00 PM
Speakers: Brian Kaspar (AveXis Inc.), R. Jude Samulski (Bamboo Therapeutics), Barry Byrne (University of Florida Powell Gene Therapy Center), Maria Escolar (University of Pittsburgh), Jakub Tolar (University of Minnesota), Kevin Flanigan (Nationwide Children's Hospital), Katherine A. High (Spark Therapeutics), and Steven J. Gray (University of North Carolina at Chapel Hill)
Gene therapy has been proposed as a promising therapeutic strategy for monogenic disorders. This symposium will explore recent advances in the field, and identify ongoing obstacles on the path to wider use of this approach.
Tuesday, March 21, 2017 | 12:00 PM - 5:00 PM
Speakers: Tsuneya Ikezu (Boston University School of Medicine), David Issadore (University of Pennsylvania), Xandra Breakefield (Massachusetts General Hospital), Efrat Levy (NYU School of Medicine), Robert A. Rissman (University of California San Diego, School of Medicine), and Andrew West (The University of Alabama at Birmingham)
In this symposium we will explore the contribution of extracellular vesicles to pathological processes underlying neurodegenerative disorders, and the appeal of exosomes as biomarkers and targets for the development of novel therapeutics.
Monday, March 13, 2017 | 9:00 AM - 4:45 PM
Speakers: Michael G. Agadjanyan (The Institute for Molecular Medicine), Bernardino Ghetti (Indiana University School of Medicine), Khalid Iqbal (New York State Institute for Basic Research in Developmental Disabilities), Viktoriya Morozova (College of Staten Island, The City University of New York), Einar M. Sigurdsson (New York University School of Medicine), Qian Wu (New York University School of Medicine), Emanuele Sher (Lilly UK), and Henrik Zetterberg (University of Gothenburg, Sweden)
This event will cover the translational potential of immunotherapy for tauopathies, reviewing the pre-clinical and clinical development of several tau immunotherapy programs that exemplify this emerging therapeutic approach.
Keynote Speaker: Costantino Iadecola (Weill Cornell Medicine)
This eBriefing covers the basic research and clinical science elucidating such mechanisms that underlie the contribution of inflammatory pathways to vascular cognitive impairment and dementia.
Featuring: Henrik Bjørn Nielsen (Clinical-Microbiomics A/S), Martin J. Blaser (New York University Langone Medical Center), Patrice D. Cani (Universite Catholique de Louvain, LDRI), Rachel Carmody (Harvard University), Stanley L. Hazen (Cleveland Clinic), Gerald I. Shulman (Yale University School of Medicine), Marion Soto (Joslin Diabetes Center, Harvard Medical School), and Dan Winer (University of Toronto)
The microbiome is emerging as an important regulator of health and disease well beyond the digestive tract. This eBriefing surveys highlights from recent research innovations and therapeutic applications from the microbiome with a focus on metabolic disease.
Organizers: Melanie Brickman Borchard (The New York Academy of Sciences), Alison Carley (The New York Academy of Sciences), Daan J.A. Crommelin (Utrecht University), Wenlei Jiang (US Food and Drug Administration), Scott McNeil (Nanotechnology Characterization Laboratory), Vinod Shah (Non Biological Complex Drugs Working Group), and Jon de Vlieger (Lygature)
This eBriefing looks at approaches for complex drug development and regulation, outstanding challenges in the assessment of complex drug equivalence, consequences for product interchangeability, and comparisons of biological and non-biological complex drug families.
Speakers: Tyrone D. Cannon (Yale University), K. Ranga Rama Krishnan (Rush Medical College), Husseini Manji (Janssen Research & Development, LLC), Vaibhav Narayan (Janssen Research & Development, LLC), Daniel Pine (National Institute of Mental Health, US National Institutes of Mental Health), and B. Timothy Walsh (New York State Psychiatric Institute, Columbia University)
At this symposium, scientists, physicians, clinicians, other allied healthcare providers, policy makers, and patients explored new scientific understanding of the neurobiology of a range of mental illnesses.